Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD77m

    Last close

    USD1.03

    ▲ 0.63 (157.50%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

InMed Pharmaceuticals and BayMedica – executive interview

InMed Pharmaceuticals and BayMedica – executive interview

InMed Pharmaceuticals — 14 videos in collection

More on this equity

Earlier today, InMed Pharmaceuticals (INM) announced that it has signed a definitive agreement to acquire BayMedica, a leading commercial manufacturer of rare cannabinoids. Both companies have strong expertise in the manufacture of rare cannabinoids, with BayMedica largely focused on chemical and biosynthesis and InMed focused on developing IntegraSyn, its proprietary platform. The combined company will be a market leader in rare cannabinoid manufacturing with the flexibility to select the most appropriate and cost-effective method based on each different cannabinoid compound.

In this interview, InMed chief executive officer Eric Adams and BayMedica chief executive officer Dr Shane Johnson discuss their shared vision for the newly combined company.

< Previous
Next >

You may also be interested in these:

Healthcare

InMed Pharmaceuticals: Edison Open House Healthcare 2022

Healthcare

InMed Pharmaceuticals – Introducing the BayMedica team

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free